Department of Medicine (Lung), Royal Marsden Hospital, London, UK.
Department of Oncology, Herlev University Hospital, Copenhagen, Denmark.
Future Oncol. 2017 Jun;13(13):1159-1171. doi: 10.2217/fon-2016-0493. Epub 2017 Feb 27.
PATIENTS & METHODS: We provide an update to a network meta-analysis evaluating the relative efficacy of nintedanib + docetaxel versus other second-line agents in adenocarcinoma histology non-small-cell lung cancer.
Overall similarity of nintedanib + docetaxel versus ramucirumab + docetaxel, and versus nivolumab. Comparing nintedanib + docetaxel with nivolumab, hazards ratio (HR) of overall survival and progression-free survival (PFS) pointed in opposite directions (overall survival: HR: 1.20 [95% credible interval: 0.92-1.58]; PFS: HR: 0.91 [0.68-1.21]). Exploratory subgroup analysis indicated superiority of nivolumab in high PD-L1 expression level subgroups; results were more favorable for nintedanib in all subgroups with low (<1%, <5%, <10%) PD-L1 expression levels - in particular, with regard to PFS.
Results demonstrated similar efficacy of nintedanib + docetaxel compared with the new therapeutic options ramucirumab + docetaxel and nivolumab, with potential differences in subgroups according to PD-L1 expression level.
我们对评估尼达尼布联合多西他赛相对于其他二线药物在非小细胞肺癌腺癌组织学中的相对疗效的网络荟萃分析进行了更新。
尼达尼布联合多西他赛与雷莫芦单抗联合多西他赛和纳武利尤单抗的总体相似性。与纳武利尤单抗相比，尼达尼布联合多西他赛的总生存期和无进展生存期（PFS）的风险比（HR）指向相反的方向（总生存期：HR：1.20[95%可信区间：0.92-1.58]；PFS：HR：0.91[0.68-1.21]）。探索性亚组分析表明，纳武利尤单抗在高 PD-L1 表达水平亚组中具有优越性；在所有 PD-L1 表达水平较低（<1%、<5%、<10%）的亚组中，尼达尼布的结果更为有利-特别是在 PFS 方面。
结果表明，尼达尼布联合多西他赛与新型治疗药物雷莫芦单抗联合多西他赛和纳武利尤单抗的疗效相似，根据 PD-L1 表达水平，亚组之间可能存在差异。
